Methods and reagents that generate a CD8 T cell immune response

Details Methods and reagents that generate a CD8 T cell immune response Methods and reagents that generate a CD8 T cell immune response

2004-04-28

2008-08-05

Parkin, Jeffrey (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Recombinant virus encoding one or more heterologous proteins...

C424S093200, C514S04400A, C536S023100

Reexamination Certificate

active

07407661

ABSTRACT:
New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.

REFERENCES:
patent: 4053582 (1977-10-01), Stickl
patent: 4748019 (1988-05-01), Lysons
patent: 5110587 (1992-05-01), Paoletti et al.
patent: 5185146 (1993-02-01), Altenburger
patent: 5225336 (1993-07-01), Paoletti
patent: 5453364 (1995-09-01), Paoletti
patent: 5462734 (1995-10-01), Letchworth, III et al.
patent: 5766597 (1998-06-01), Paoletti et al.
patent: 5846546 (1998-12-01), Hurwitz et al.
patent: 6103244 (2000-08-01), Dorner et al.
patent: 6663871 (2003-12-01), McMichael et al.
patent: 2003/0138454 (2003-07-01), Hill et al.
patent: 2004/0018177 (2004-01-01), Hill et al.
patent: 2004/0131594 (2004-07-01), McMichael et al.
patent: 2004/0171272 (2004-09-01), McMichael et al.
patent: 2004/0175365 (2004-09-01), McMichael et al.
patent: 2004/0213799 (2004-10-01), McMichael et al.
patent: 2005/0025747 (2005-02-01), Laidlaw et al.
patent: 2005/0175627 (2005-08-01), Schneider
patent: 1 324 661 (2001-12-01), None
patent: 0 638 316 (1995-02-01), None
patent: 0 753 581 (1997-01-01), None
patent: 0 517 292 (2000-02-01), None
patent: WO 92/22641 (1992-12-01), None
patent: WO 93/03145 (1993-02-01), None
patent: WO 96/26271 (1996-08-01), None
patent: WO 97/39771 (1997-10-01), None
patent: WO 98/04728 (1998-02-01), None
patent: WO 98/56919 (1998-12-01), None
patent: WO 99/41383 (1999-08-01), None
patent: WO 01/02607 (2001-01-01), None
patent: WO 01/14416 (2001-03-01), None
patent: WO 01/21201 (2001-03-01), None
patent: WO 01/85932 (2001-11-01), None
patent: WO 01/85932 (2001-11-01), None
patent: WO 02/24224 (2002-03-01), None
patent: WO 02/068654 (2002-09-01), None
patent: WO 02/068654 (2002-09-01), None
patent: WO 2005/026370 (2005-03-01), None
patent: WO 2005/030964 (2005-04-01), None
patent: WO 2006/061643 (2006-06-01), None
patent: WO 2006/120474 (2006-11-01), None
patent: WO 2006/125983 (2006-11-01), None
Davis, H. DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. Vaccine 1996, vol. 14, No. 9, p. 910-915.
Puig et al. CD4+ Immune Escape and Subsequent T-Cell Failure Following Chimpanzee Immunization Against Hepatitis C Virus. Hepatology Sep. 2006, vol. 44, p. 736-745.
Koziel. The role of immune responses in the pathogenesis of hepatitis C virus infection. Journal of Viral Pathology 1997. vol. 4 Suppl 2, p. 31-41. Abstract only provided.
Koziel et al. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Spriner Seminars in Immunopathology 1997, vol. 19(1), p. 69-83. Abstract only provided.
Picard et al. Complication of intramuscular/subcutaneous immune therapy in severely immune-compromised individuals. Journal of Acquired Immune Deficiency Syndromes 1991, vol. 4(6), p. 641-643.
Ho, M. AIDS Vaccines Trials Dangerous. isis news No. 11/12 [online]. Institute of Science in Society, Oct. 2001 [retrieved on Nov. 27, 2006]. Retrieved from the Internet <URL: www.i-sis.org.uk/isisnews/i-sisnews11-19.php>.
Ada, G., “Do Cytotoxic T Lymphocytes Clear Home HIV/SIV Infections?,”J. Med. Primatol. 25(3):158-162 (Jun. 1996).
Aidoo, M., et al., “Identification of Conserved Antigenic Components For A Cytotoxic T Lymphocyte-Inducing Vaccine Against Malaria,”Lancet 345(8956):1003-1007 (Apr. 22, 1995).
Aidoo, M., et al., “Recombinant Vaccinia Viruses for the Characterization ofPlasmodium falciparum-specific Cytotoxic T Lymphocytes: Recognition of Processed Antigen Despite Limited Re-Stimulation Efficacy,”Intl. Immunol. 9(5):731-737 (Jan. 1997).
Allsopp, C.E.M., et al., “Comparison of Numerous Delivery Systems for the Induction of Cytotoxic T Lymphocytes By Immunization,”Eur. J. Immunol. 26:1951-1959 (1996).
Blanchard, T., et al., “Future Vaccines for HIV,”Lancet 348(9043):1741 (Dec. 1996).
Blanchard, T.J., et al., “Modified Vaccinia Virus Ankara Undergoes Limited Replication in Human Cells and Lacks Several Immunomodulatory Proteins: Implications for Use as a Human Vaccine,”J. Gen. Virol 79:1159-1167 (1998).
Carroll, M.W., et al., “Highly Attenuated Modified Vaccinia Virus Ankara (MVA) as an Effective Recombinant Vector: A Murine Tumor Model,”Vaccine15(4):387-394 (1997).
Chamberlain, R.S., et al., “Use of Multiple Vaccination Vectors for the Generation of CTL Against a Model Tumor Antigen,”Proceedings of the Annual Meeting of the American Association for Cancer Research(Washington, Apr. 20-24, 1996, 37, Abstract No. 3263).
Doolan, D.L., “The Complexity of Protective Immunity Against Live-Stage Malaria,”J. Immunol., 165(3):1453-1462 (2000).
Doolan, D.L., et al., “Circurmventing Genetic Restriction of Protection against Malaria with Mulitgene DNA Immunization: CD8 T Cell-, Interferon γ-, and Nitric Oxide-Dependent Immunity,”J. Exp. Med . 183(4):1739-1746 (Apr. 1996).
Fuller, D.H., et al., “Gene Gun-Based Nucleic Acid Immunization Alone or in Combination with Recombinant Vaccinia Vectors Suppresses Virus Burden in Rhesus Macaques Challenged with a Heterologous SIV,”Immunol. Cell Biol. 75(4):389-396 (Aug. 1997).
Fuller, D.H., et al., “Enhancement of Immunodeficiency Virus-Specific Immune Responses in DNA-Immunized Rhesus Macaques,”Vaccine, 15(8):924-926 (Jun. 1997).
Gallimore, A., et al., “Early Suppression of SIV Replication By CD830nef-specific Cytotoxic T Cells In Vaccinated Macaques,”Nature Med. 1(11):1167-1173 (Nov. 1995).
Gilbert, S.C., et al., “A Protein Particle Vaccine Containing Multiple Malaria Epitopes,”Nat. Biotechnol., 15(12):1280-1284 (1997).
Greenspan, N.S., et al., “Defining Epitopes: It's Not As Easy As It Seems,”Nature Biotechnology 7:939-937 (1999).
Hanke, T., et al., “Immunogenicities of Intravenous and Intramuscular Administrations of Modified Vaccinia Virus Ankara-Based Multi-CTL Epitope Vaccine for Human Immunodeficiency Virus Type 1 in Mice,”J. Gen. Virol. 79:83-90 (1998).
Hanke, T., et al., “Enhancement of MHC Class I-Restricted Peptide-Specific T Cell Induction by a DNA Prime/MVA Boost Vaccination Regime,”Vaccine 16(5):439-445 (1998).
Hanke, T., et al., “DNA Multi-CTL Epitope Vaccine for HIV andPlasmodium falciparum: Immunogenicity in Mice,”Vaccine 16(4):426-435 (1998).
Hill, AV, “DNA-Based Vaccines for Malaria: a Heterologous Prime-Boost Immunisation Strategy,”Dev. Biol. (Basel), 104:171-179 (2000).
Hill, A. V.S., et al., “Common West African HLA Antigens Are Associated With Protection From Severe Malaria,”Nature 352(6336):595-600 (Aug. 15, 1991).
Hirsch, V.M., et al., “Patterns of Viral Replication Correlate with Outcome in Simian Immunodeficiency Virus (SIV)-Infected Macaques: Effect of Prior Immunization with a Trivalent SIV Vaccine in Modified Vaccinia Virus Ankara,”J. Virol. 70(6):3741-3752 (Jun. 1996).
Hodge, J.W., et al., “Diversified Prime and Boost Protocols Using Recombinant Vaccinia Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses,”Vaccine 15(6/7):759-768 (Apr./May 1997).
Huygen, K., et al., “Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine,”Nat. Med. 2: 893-898 (1996).
Irvine, K.R., et al., “Route of Immunization and the Therapeutic Impact of Recombinant Anticaner Vaccines,”J. Natl. Cancer Inst. 89(5):390-392 (Mar. 1997).
Irvine, K.R., et al., “Enhancing Efficacy of Recombinant Anticancer Vaccines With Prime/Boost Regiments That Use Two Different Vectors,”J. Natl. Cancer Inst

Affiliated with

Also associated with

Rating

Methods and reagents that generate a CD8 T cell immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and reagents that generate a CD8 T cell immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and reagents that generate a CD8 T cell immune response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4020072